Cargando…
Activation of AMPK sensitizes medulloblastoma to Vismodegib and overcomes Vismodegib‐resistance
Vismodegib, a Smoothened antagonist, is clinically approved for treatment of human basal cell carcinoma (BCC), in the clinical trials of medulloblastoma (MB) and other cancers. However, a significant proportion of these tumors fail to respond to Vismodegib after a period of treatment. Here, we find...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171304/ https://www.ncbi.nlm.nih.gov/pubmed/34124601 http://dx.doi.org/10.1096/fba.2020-00032 |